MGL-3196 clinical trials

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

This study is testing a new medicine, MGL-3196, for people with a type of liver disease called NASH. Researchers want to see if the medicine can improve liver health and stop the disease from getting worse. It involves regular check-ups and liver biopsies.